Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Hikma Pharmaceuticals (HKMPY) Stock Price & Analysis

43 Followers

HKMPY Stock Chart & Stats

$47.47$0.71(1.51%)
At close: 4:00 PM EST
$40$42.5$45Jul 13Jul 27Aug 6Aug 24Oct 9
Day’s Range
$47.47 - $47.47
52-Week Range
$31.91 - $47.47
Previous Close
$46.77
Volume
N/A
Average Volume (3M)
30
Market Cap
$4.87B
Enterprise Value
$6.09B
Total Cash (Recent Filing)
$289.00M
Total Debt (Recent Filing)
$1.96B
Price to Earnings (P/E)
13.3
Beta
0.49
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Aug 17, 2026
Dividend Yield
3.55%

Bulls Say, Bears Say

Bulls Say

Diversified Commercial Footprint; Strong MENA Branded Performance

Hikma's mix across branded, generics and injectables reduces single-market risk; MENA branded outperformance delivers mid-to-high single-digit growth and mid-20s margins, providing a durable, higher-margin revenue base supported by local brands, tenders and an established salesforce.

Injectables Stabilized With Capacity And CMO Growth Roadmap

Operational fixes and ongoing capacity builds (Cherry Hill, Bedford 2028) plus explicit CMO targets strengthen manufacturing competitiveness and supply reliability. These investments underpin durable contract manufacturing revenue growth and higher barriers to entry for competitors over the next multi-year horizon.

Consistent Revenue Growth And Improving Profitability

Top-line acceleration and margin recovery across 2023–2025 reflect better mix, cost control and execution. Sustained revenue growth with improving margins enhances cash generation potential and supports reinvestment in R&D, capacity and branded market expansion over the medium term.

Bears Say

Weak Operating Cash Flow And Poor Cash Conversion

Cash generation has deteriorated with FCF falling sharply and covering less than half of net income. Persistent weak cash conversion undermines the company's ability to fund capex, pay down debt, pursue M&A or sustain shareholder returns without relying on external financing, a material fundamental constraint.

Rising Leverage Reduces Financial Flexibility

Material debt growth and higher debt/equity erode balance sheet flexibility. In a sector with pricing pressure and investment needs, elevated leverage increases interest burden and constrains discretionary spending, amplifying downside risk if earnings or cash flow weaken.

Pricing Pressure And Competition In Oral Generics

Sustained price erosion in parts of the oral generics portfolio compresses margins and limits cash generation. Structural competitive intensity requires continuous product launches, cost efficiency or premium branded growth to offset margin degradation over the medium term.

Hikma Pharmaceuticals News

HKMPY FAQ

What was Hikma Pharmaceuticals’s price range in the past 12 months?
Hikma Pharmaceuticals lowest stock price was $31.91 and its highest was $47.47 in the past 12 months.
What is Hikma Pharmaceuticals’s market cap?
Hikma Pharmaceuticals’s market cap is $4.87B.
When is Hikma Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hikma Pharmaceuticals’s earnings last quarter?
Hikma Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported $2.106 earnings per share for the quarter.
Is Hikma Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Hikma Pharmaceuticals pay dividends?
Hikma Pharmaceuticals pays a Semiannually dividend of $0.76 which represents an annual dividend yield of 3.55%. See more information on Hikma Pharmaceuticals dividends here
What is Hikma Pharmaceuticals’s EPS estimate?
Hikma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals have?
Hikma Pharmaceuticals has 104,373,820 shares outstanding.
What happened to Hikma Pharmaceuticals’s price movement after its last earnings report?
Hikma Pharmaceuticals reported an EPS of $2.106 in its last earnings report. Following the earnings report the stock price went up 8.044%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals?
Currently, no hedge funds are holding shares in HKMPY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology